GTBPGT Biopharma Inc
$0.41
$0.0028
(0.67%)
Closed $0.4152
$0.0052
(1.25%)
After Hours
Reported EarningsAug 6
Mkt Cap$15.07M
Vol547,299.00
Fundamentals
Mkt Cap
$15.07M
Volume
-
52W High
$3.85
52W Low
$0.261
PE Ratio
-0.03
Avg. Volume
2.21M
EPS (Annual)
-$6.25
Rev/Employee
$0.00
Earnings
Aug 06
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...
PR Newswire
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield new pre-IND candidates by 2027.read more...
Benzinga
The $13 Million Company Teaching the Immune System to Hunt Cancer
The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...
PR Newswire
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...
PR Newswire
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic PR Newswire SAN FRANCISCO, May 18, 2026 Issued on behalf of GT Biopharma, Inc.SAN FRANCISCO, May 18, 2026 /PRNewswire/ -- USA News Group...
PR Newswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...
PR Newswire
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
GT Biopharma doses first patient in Phase 1 GTB-5550 trial targeting B7-H3-positive solid tumors with subcutaneous TriKE therapy.read more...
Benzinga
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know
GT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape PR Newswire VANCOUVER, BC, Jan. 16, 2026 Issued on behalf...
PR Newswire
<
1
2
...
>